Oct 01, 2019
Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
Sep 30, 2019
Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer
Sep 17, 2019
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
Sep 11, 2019
Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors
Aug 28, 2019
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
Aug 05, 2019
AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
Jul 29, 2019
Neurocrine Biosciences Reports Second Quarter 2019 Financial Results
Jul 10, 2019
Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease
Jul 08, 2019
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results
Jun 19, 2019
World Endometriosis Markets, 2014-2019 & 2019-2026: Key Pipeline and Marketed Drugs, Clinical Trials, Upcoming and Regulatory Events, Patent Information, Licensing and Acquisition Deals
Jun 11, 2019
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders
Jun 04, 2019
Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference
May 30, 2019
Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference
May 20, 2019
Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life
May 07, 2019
Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019
May 06, 2019
Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients
May 05, 2019
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
Apr 30, 2019
Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting
Apr 08, 2019
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results
Mar 12, 2019
Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia